Table 3.
Bias assessment of studies included in the meta-analysis.
| Cochrane risk of bias table on the Prognosis for Patients with resectable HCC |
|||||
|---|---|---|---|---|---|
| Kaibori [19] | Zhou [20] | Yamasaki [22] | Wu [23] | Cui [21] | |
| Random sequence generation | Unclear risk (the method of randomizationgeneration was not described) | Unclear risk (the method of randomizationgeneration was not described) | Unclear risk (the method of randomizationgeneration was not described) | Unclear risk (the method of randomizationgeneration was not described) | Unclear risk (the method of randomizationgeneration was not described) |
| Allocation concealment | Unclear risk (whether using sealed, opaque or successive coded envelope was not mentioned) | Low risk (Using sealed, opaque and successive coded envelope) | Unclear risk (whether using sealed, opaque or successive coded envelope was not mentioned) | Unclear risk (information is not complete) | Unclear risk (information is not complete) |
| Blinding of outcomes | Unclear risk (information was not complete) | Unclear risk (information was not complete) | Unclear risk (information was not complete) | Unclear risk (information was not complete) | Unclear risk (information was not complete) |
| Incomplete outcomedata | Low risk (the results were relatively complete, missing data could be ignored) | Low risk (the results were relatively complete, missing data could be ignored) | High risk (incidence of loss to follow-up was up to 10% in pre-TACE group and 20% incontrol group) | Unclear risk (no direct data about overallsurvival and disease free survival) | High risk (the data of overall survival rate was incomplete) |
| Selective reporting | Low risk (predetermined indicators were definite) | Low risk (predetermined indicators were definite) | High risk (incomplete data and uncertainprimary outcome indicators) | High risk (incomplete data and uncertainprimary outcome indicators) | High risk (incomplete data and uncertainprimary outcome indicators) |
| Other bias | High risk (significantly different in the level of AFP and tumor stage among groups) | Unclear risk (information was not complete) | Unclear risk (information was not complete) | Unclear risk (information was not complete) | Unclear risk (information was not complete) |